Is IMVT or ALVO more profitable?

Immunovant has a net margin of 0.00% compared to Alvotech's net margin of -36.31%. Alvotech's return on equity of 0.00% beat Immunovant's return on equity. Company Net Margins Return on Equity Return on Assets Immunovant N/A -69.59% -62.49% Alvotech -36.31% N/A -11.73%

Does the media favor IMVT or ALVO?

In the previous week, Immunovant had 6 more articles in the media than Alvotech. MarketBeat recorded 7 mentions for Immunovant and 1 mentions for Alvotech. Alvotech's average media sentiment score of 0.27 beat Immunovant's score of 0.13 indicating that Alvotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunovant 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Alvotech 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation & earnings, ALKS or ALVO?

Alkermes has higher revenue and earnings than Alvotech. Alvotech is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alkermes $1.48B 4.75 $241.66M $0.38 109.87 Alvotech $588.90M 2.79 $27.92M -$0.61 N/A

Is ALKS or ALVO more profitable?

Alkermes has a net margin of 3.96% compared to Alvotech's net margin of -36.31%. Alkermes' return on equity of 4.15% beat Alvotech's return on equity. Company Net Margins Return on Equity Return on Assets Alkermes 3.96% 4.15% 2.19% Alvotech -36.31% N/A -11.73%

Does the media prefer ALKS or ALVO?

In the previous week, Alkermes had 4 more articles in the media than Alvotech. MarketBeat recorded 5 mentions for Alkermes and 1 mentions for Alvotech. Alkermes' average media sentiment score of 0.42 beat Alvotech's score of 0.27 indicating that Alkermes is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alkermes 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Alvotech 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor ALVO or RYTM?

In the previous week, Rhythm Pharmaceuticals had 3 more articles in the media than Alvotech. MarketBeat recorded 4 mentions for Rhythm Pharmaceuticals and 1 mentions for Alvotech. Alvotech's average media sentiment score of 0.27 beat Rhythm Pharmaceuticals' score of 0.26 indicating that Alvotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alvotech 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Rhythm Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer IOVA or ALVO?

In the previous week, Iovance Biotherapeutics had 48 more articles in the media than Alvotech. MarketBeat recorded 49 mentions for Iovance Biotherapeutics and 1 mentions for Alvotech. Iovance Biotherapeutics' average media sentiment score of 0.71 beat Alvotech's score of 0.27 indicating that Iovance Biotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Iovance Biotherapeutics 12 Very Positive mention(s) 8 Positive mention(s) 11 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alvotech 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings & valuation, CGON or ALVO?

Alvotech has higher revenue and earnings than CG Oncology. CG Oncology is trading at a lower price-to-earnings ratio than Alvotech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CG Oncology $4.04M 1,478.36 -$160.99M -$2.69 N/A Alvotech $588.90M 2.79 $27.92M -$0.61 N/A

Is CGON or ALVO more profitable?

Alvotech has a net margin of -36.31% compared to CG Oncology's net margin of -3,602.68%. Alvotech's return on equity of 0.00% beat CG Oncology's return on equity. Company Net Margins Return on Equity Return on Assets CG Oncology -3,602.68% -25.20% -23.98% Alvotech -36.31% N/A -11.73%

Alvotech (ALVO) Competitors

$5.45 -0.17 (-3.02%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$5.45 0.00 (0.00%)

As of 10/2/2026 07:30 PM Eastern

Compare

ALVO vs. IMVT, ALKS, RYTM, IOVA, and CGON

Should you buy Alvotech stock or one of its competitors? Alvotech's main competitors and comparable companies include Immunovant (IMVT), Alkermes (ALKS), Rhythm Pharmaceuticals (RYTM), Iovance Biotherapeutics (IOVA), and CG Oncology (CGON). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Alvotech compare to Immunovant?

Immunovant (NASDAQ:IMVT) and Alvotech (NASDAQ:ALVO) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, risk, earnings, dividends, valuation, analyst recommendations, institutional ownership and media sentiment.

Immunovant has a beta of 0.84, meaning that its stock price is 16% less volatile than the broader market. Comparatively, Alvotech has a beta of 0.2, meaning that its stock price is 80% less volatile than the broader market.

Immunovant has a net margin of 0.00% compared to Alvotech's net margin of -36.31%. Alvotech's return on equity of 0.00% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunovant	N/A	-69.59%	-62.49%
Alvotech	-36.31%	N/A	-11.73%

In the previous week, Immunovant had 6 more articles in the media than Alvotech. MarketBeat recorded 7 mentions for Immunovant and 1 mentions for Alvotech. Alvotech's average media sentiment score of 0.27 beat Immunovant's score of 0.13 indicating that Alvotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunovant	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Alvotech	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

47.1% of Immunovant shares are held by institutional investors. 1.9% of Immunovant shares are held by company insiders. Comparatively, 0.5% of Alvotech shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Alvotech has higher revenue and earnings than Immunovant. Immunovant is trading at a lower price-to-earnings ratio than Alvotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunovant	N/A	N/A	-$505.61M	-$2.82	N/A
Alvotech	$588.90M	2.79	$27.92M	-$0.61	N/A

Immunovant presently has a consensus target price of $44.00, indicating a potential upside of 30.87%. Alvotech has a consensus target price of $8.50, indicating a potential upside of 55.96%. Given Alvotech's higher possible upside, analysts clearly believe Alvotech is more favorable than Immunovant.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunovant	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58
Alvotech	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Alvotech beats Immunovant on 8 of the 15 factors compared between the two stocks.

How does Alvotech compare to Alkermes?

Alkermes (NASDAQ:ALKS) and Alvotech (NASDAQ:ALVO) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, analyst recommendations, dividends, earnings, risk, valuation and institutional ownership.

Alkermes presently has a consensus target price of $54.47, suggesting a potential upside of 30.47%. Alvotech has a consensus target price of $8.50, suggesting a potential upside of 55.96%. Given Alvotech's higher probable upside, analysts clearly believe Alvotech is more favorable than Alkermes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alkermes	1 Sell rating(s)	5 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.74
Alvotech	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Alkermes had 4 more articles in the media than Alvotech. MarketBeat recorded 5 mentions for Alkermes and 1 mentions for Alvotech. Alkermes' average media sentiment score of 0.42 beat Alvotech's score of 0.27 indicating that Alkermes is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alkermes	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Alvotech	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Alkermes has a net margin of 3.96% compared to Alvotech's net margin of -36.31%. Alkermes' return on equity of 4.15% beat Alvotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alkermes	3.96%	4.15%	2.19%
Alvotech	-36.31%	N/A	-11.73%

95.2% of Alkermes shares are held by institutional investors. 4.6% of Alkermes shares are held by insiders. Comparatively, 0.5% of Alvotech shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Alkermes has a beta of 0.32, indicating that its share price is 68% less volatile than the broader market. Comparatively, Alvotech has a beta of 0.2, indicating that its share price is 80% less volatile than the broader market.

Alkermes has higher revenue and earnings than Alvotech. Alvotech is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alkermes	$1.48B	4.75	$241.66M	$0.38	109.87
Alvotech	$588.90M	2.79	$27.92M	-$0.61	N/A

Summary

Alkermes beats Alvotech on 16 of the 17 factors compared between the two stocks.

How does Alvotech compare to Rhythm Pharmaceuticals?

Alvotech (NASDAQ:ALVO) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability, media sentiment and risk.

In the previous week, Rhythm Pharmaceuticals had 3 more articles in the media than Alvotech. MarketBeat recorded 4 mentions for Rhythm Pharmaceuticals and 1 mentions for Alvotech. Alvotech's average media sentiment score of 0.27 beat Rhythm Pharmaceuticals' score of 0.26 indicating that Alvotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alvotech	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Rhythm Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Alvotech has a net margin of -36.31% compared to Rhythm Pharmaceuticals' net margin of -85.59%. Alvotech's return on equity of 0.00% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alvotech	-36.31%	N/A	-11.73%
Rhythm Pharmaceuticals	-85.59%	-159.87%	-44.00%

Alvotech presently has a consensus target price of $8.50, indicating a potential upside of 55.96%. Rhythm Pharmaceuticals has a consensus target price of $140.67, indicating a potential upside of 51.53%. Given Alvotech's higher probable upside, equities analysts clearly believe Alvotech is more favorable than Rhythm Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alvotech	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Rhythm Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	17 Buy rating(s)	0 Strong Buy rating(s)	2.76

Alvotech has a beta of 0.2, suggesting that its share price is 80% less volatile than the broader market. Comparatively, Rhythm Pharmaceuticals has a beta of 2.01, suggesting that its share price is 101% more volatile than the broader market.

Alvotech has higher revenue and earnings than Rhythm Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Alvotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alvotech	$588.90M	2.79	$27.92M	-$0.61	N/A
Rhythm Pharmaceuticals	$189.76M	33.52	-$196.54M	-$3.11	N/A

Summary

Alvotech beats Rhythm Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

How does Alvotech compare to Iovance Biotherapeutics?

Iovance Biotherapeutics (NASDAQ:IOVA) and Alvotech (NASDAQ:ALVO) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, earnings, risk, institutional ownership, dividends and valuation.

77.0% of Iovance Biotherapeutics shares are held by institutional investors. 7.8% of Iovance Biotherapeutics shares are held by insiders. Comparatively, 0.5% of Alvotech shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Alvotech has higher revenue and earnings than Iovance Biotherapeutics. Iovance Biotherapeutics is trading at a lower price-to-earnings ratio than Alvotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Iovance Biotherapeutics	$263.50M	24.44	-$390.98M	-$0.73	N/A
Alvotech	$588.90M	2.79	$27.92M	-$0.61	N/A

Iovance Biotherapeutics currently has a consensus price target of $12.40, indicating a potential downside of 12.80%. Alvotech has a consensus price target of $8.50, indicating a potential upside of 55.96%. Given Alvotech's higher possible upside, analysts clearly believe Alvotech is more favorable than Iovance Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Iovance Biotherapeutics	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.67
Alvotech	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Iovance Biotherapeutics had 48 more articles in the media than Alvotech. MarketBeat recorded 49 mentions for Iovance Biotherapeutics and 1 mentions for Alvotech. Iovance Biotherapeutics' average media sentiment score of 0.71 beat Alvotech's score of 0.27 indicating that Iovance Biotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Iovance Biotherapeutics	12 Very Positive mention(s)	8 Positive mention(s)	11 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alvotech	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Alvotech has a net margin of -36.31% compared to Iovance Biotherapeutics' net margin of -89.11%. Alvotech's return on equity of 0.00% beat Iovance Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Iovance Biotherapeutics	-89.11%	-40.51%	-31.65%
Alvotech	-36.31%	N/A	-11.73%

Iovance Biotherapeutics has a beta of 0.76, suggesting that its share price is 24% less volatile than the broader market. Comparatively, Alvotech has a beta of 0.2, suggesting that its share price is 80% less volatile than the broader market.

Summary

Iovance Biotherapeutics and Alvotech tied by winning 8 of the 16 factors compared between the two stocks.

How does Alvotech compare to CG Oncology?

CG Oncology (NASDAQ:CGON) and Alvotech (NASDAQ:ALVO) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, valuation, risk, earnings, media sentiment and institutional ownership.

In the previous week, Alvotech had 1 more articles in the media than CG Oncology. MarketBeat recorded 1 mentions for Alvotech and 0 mentions for CG Oncology. Alvotech's average media sentiment score of 0.27 beat CG Oncology's score of 0.00 indicating that Alvotech is being referred to more favorably in the news media.

Company	Overall Sentiment
CG Oncology	Neutral
Alvotech	Neutral

Alvotech has a net margin of -36.31% compared to CG Oncology's net margin of -3,602.68%. Alvotech's return on equity of 0.00% beat CG Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CG Oncology	-3,602.68%	-25.20%	-23.98%
Alvotech	-36.31%	N/A	-11.73%

Alvotech has higher revenue and earnings than CG Oncology. CG Oncology is trading at a lower price-to-earnings ratio than Alvotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CG Oncology	$4.04M	1,478.36	-$160.99M	-$2.69	N/A
Alvotech	$588.90M	2.79	$27.92M	-$0.61	N/A

CG Oncology presently has a consensus target price of $87.78, indicating a potential upside of 30.27%. Alvotech has a consensus target price of $8.50, indicating a potential upside of 55.96%. Given Alvotech's higher probable upside, analysts plainly believe Alvotech is more favorable than CG Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CG Oncology	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Alvotech	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

26.6% of CG Oncology shares are held by institutional investors. 4.8% of CG Oncology shares are held by company insiders. Comparatively, 0.5% of Alvotech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

CG Oncology has a beta of 0.28, suggesting that its share price is 72% less volatile than the broader market. Comparatively, Alvotech has a beta of 0.2, suggesting that its share price is 80% less volatile than the broader market.

Summary

Alvotech beats CG Oncology on 10 of the 16 factors compared between the two stocks.

Get Alvotech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALVO vs. The Competition

Export

Metric	Alvotech	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.64B	$3.85B	$7.15B	$13.28B
Dividend Yield	N/A	3.65%	2.54%	17.33%
P/E Ratio	-8.93	13.00	274.71	26.04
Price / Sales	2.79	1,288.64	656.46	105.16
Price / Cash	25.01	123.39	78.87	52.62
Price / Book	-5.80	16.57	10.93	6.31
Net Income	$27.92M	-$22.66M	$3.51B	$362.16M
7 Day Performance	-5.22%	-2.97%	-2.00%	-1.66%
1 Month Performance	2.44%	-10.82%	-6.19%	-4.68%
1 Year Performance	-34.50%	19.00%	8.03%	1.57%

Alvotech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ALVO Alvotech	3.0225 of 5 stars	$5.45 -3.0%	$8.50 +56.0%	-34.5%	$1.64B	$588.90M	N/A	1,460	Positive News
IMVT Immunovant	1.8461 of 5 stars	$33.46 -0.1%	$44.00 +31.5%	+98.9%	$6.91B	N/A	N/A	315
ALKS Alkermes	3.0512 of 5 stars	$40.80 +1.6%	$54.47 +33.5%	+34.4%	$6.84B	$1.48B	107.37	2,050
RYTM Rhythm Pharmaceuticals	2.6927 of 5 stars	$95.71 -2.9%	$140.67 +47.0%	-6.3%	$6.56B	$189.76M	N/A	414
IOVA Iovance Biotherapeutics	1.7089 of 5 stars	$14.45 +31.5%	$11.78 -18.5%	+507.7%	$6.55B	$263.50M	N/A	975	Trending News Analyst Forecast Analyst Revision High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ALVO) was last updated on 10/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Alvotech (ALVO) Competitors

ALVO vs. IMVT, ALKS, RYTM, IOVA, and CGON

How does Alvotech compare to Immunovant?

Summary

How does Alvotech compare to Alkermes?

Summary

How does Alvotech compare to Rhythm Pharmaceuticals?

Summary

How does Alvotech compare to Iovance Biotherapeutics?

Summary

How does Alvotech compare to CG Oncology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALVO vs. The Competition

Alvotech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Alvotech (ALVO) Competitors

ALVO vs. IMVT, ALKS, RYTM, IOVA, and CGON

How does Alvotech compare to Immunovant?

Which has more risk and volatility, IMVT or ALVO?

Is IMVT or ALVO more profitable?

Does the media favor IMVT or ALVO?

Do insiders & institutionals hold more shares of IMVT or ALVO?

Which has stronger valuation and earnings, IMVT or ALVO?

Do analysts prefer IMVT or ALVO?

Summary

How does Alvotech compare to Alkermes?

Do analysts recommend ALKS or ALVO?

Does the media prefer ALKS or ALVO?

Is ALKS or ALVO more profitable?

Do insiders and institutionals hold more shares of ALKS or ALVO?

Which has more volatility & risk, ALKS or ALVO?

Which has better valuation & earnings, ALKS or ALVO?

Summary

How does Alvotech compare to Rhythm Pharmaceuticals?

Does the media favor ALVO or RYTM?

Is ALVO or RYTM more profitable?

Do analysts rate ALVO or RYTM?

Which has more volatility & risk, ALVO or RYTM?

Which has preferable valuation & earnings, ALVO or RYTM?

Summary

How does Alvotech compare to Iovance Biotherapeutics?

Do insiders & institutionals believe in IOVA or ALVO?

Which has better valuation and earnings, IOVA or ALVO?

Do analysts rate IOVA or ALVO?

Does the media prefer IOVA or ALVO?

Is IOVA or ALVO more profitable?

Which has more risk and volatility, IOVA or ALVO?

Summary

How does Alvotech compare to CG Oncology?

Does the media prefer CGON or ALVO?

Is CGON or ALVO more profitable?

Which has preferable earnings & valuation, CGON or ALVO?

Do analysts rate CGON or ALVO?

Do insiders and institutionals believe in CGON or ALVO?

Which has more volatility and risk, CGON or ALVO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALVO vs. The Competition

Alvotech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools